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Abstract 
A 32 factorial design was employed to produce oral sustained release 
lipospheres prepared by modified double emulsion solvent evaporation 
technique for Serratiopeptidase (acid-labile enzyme) using wax and polar 
lipid combination as retardants. The effects of formulation variables selected 
through preliminary trials namely peptide and stabilizer (Tween® 80) 
concentration was evaluated by F-test on the drug content and size of 
lipospheres. The results of analysis of variance tests for both effects indicated 
that the test is significant (p < 0.05). The effect of Tween® 80 concentration 
(SSY1- 41.66; SSY2 – 25.30) was found to be higher than peptide amount 
(SSY1- 3.94; SSY2 – 4.03) on the size and drug content of lipospheres. 
Characterization was carried out through photomicroscopy, scanning electron 
microscopy, particle size analysis and in vitro drug release study. The effect 
of formulation variables on the integrity of enzyme was confirmed by in vitro 
proteolytic activity. The drug release from lipospheres followed first-order 
kinetics and was characterized by the Higuchi diffusion and Ritger-Peppas 
model. Lipospheres having maximum drug content (11.93±0.89) released 3-
4% enzyme at pH 1.2 in 4 h. In phosphate buffer, lipospheres showed an 
initial burst release of 20.89±1.87% to 27.89±2.03% in one hour with 
additional 73.22±2.36% to 94.75±2.78% in next 12 hours. Thus, peptide 
loaded lipospheres with desirable characters in terms of maximum peptide 
content and diffusion release pattern were successfully prepared with 
formulation optimization approach. 
 
Keywords: Cetyl alcohol, Enzyme, factorial design, Lipospheres; Peptide, 
Serratiopeptidase 
 
Introduction  
Proteins and polypeptides are important classes of 
bioactive agents that play key roles in controlling 
various body functions required for good health when 
administered in the correct quantities at the appropriate 
body site and at the correct time. Proteins and peptides 
have many attractive properties but they also have 
disadvantages that limit their widespread acceptance by 
patients and physicians such as numerous chemical and 
physical instability mechanisms, rapid enzymatic 
degradation which is responsible for low oral and 
transdermal bioavailability and short in vivo half lives, 
doi:10.5138/ijdd.2009.0975.0215.01002 
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which often necessitate their frequent delivery [1]. The 
development of delivery systems for this rapidly 
expanding class of therapeutic agents is the major 
challenge. 
Polymeric delivery systems represent an interesting 
strategy particularly oral multiparticulate systems that 
show more predictable gastric emptying, high degree of 
dispersion in the digestive tract, lesser risk of dose 
dumping and reduced local irritation [2,3]. But, the use 
of synthetic polymer matrix materials often goes along 
with detrimental effects on incorporated peptides 
during manufacturing of the formulations or during the 
erosion of the polymers after application [4]. 
Moreover, the degradation of polymer might possibly 
cause systemic toxic effects through the impairment of 
reticuloendothelial system (RES) or after phagocytosis 
of particles by human macrophages and granlocytes 
[5]. Therefore, alternative carrier substances have been 
investigated; among them lipidic materials have 
garnered growing attention. Numerous lipid based 
delivery systems such as liposomes, solid lipid 
nanoparticles, oily suspensions, submicron lipid 
emulsions, lipid implants, lipid microtubules and 
microcylinders, lipid microbubbles and lipid 
microspheres (Lipospheres) have been investigated for 
proteins and peptides [6]. 
The lipospheres carrier system has several advantages 
over other delivery systems in term of physical 
stability, low cost of ingredients, ease of preparation 
and scale-up, high dispersability in an aqueous 
medium, high entrapment of hydrophobic drugs, 
controlled particle size and extended release of 
entrapped drug [7]. The liposphere drug delivery 
system is an aqueous microdispersion of solid water 
insoluble spherical microparticles of a particle size 
between 0.2 and 100 µm. The lipospheres are made of 
solid hydrophobic triglycerides having a monolayer of 
phospholipids embedded on the surface of the particle. 
The solid core contains the bioactive compound 
dissolved or dispersed in a solid fat matrix. These are 
generally used as carrier vehicle for hydrophobic drugs. 
These exhibit low entrapment of hydrophilic drugs 
which could be improved by using polar lipids like 
cetyl alcohol, stearyl alcohol and cetostearyl alcohol 
etc [8].  
Method of preparation has much influence on the 
properties of lipospheres and therefore the desired 
properties were kept in mind during the selection of a 
particular method of preparation. For the formulation 
of lipospheres certain requirements were optimal 
protein loading, high yield, high encapsulation 
efficiency, stability of the encapsulated protein, batch 
uniformity and inter-batch reproducibility, adjustable 
release profiles, low burst effect and free-flowing 
lipospheres.  
Polypeptides and proteins like proteolytic enzymes 
(e.g., Serratiopeptidase, STP) offer a powerful 
treatment for pain and inflammation with widespread 
use in arthritis, fibrocystic breast disease, chronic 
bronchitis, sinusitis, atherosclerosis, wound 
debridement, and carpal tunnel syndrome [9]. These 
produce pharmacological effects by absorption through 
the intestines into the blood stream [10]. But, oral 
bioavailability of these peptide drugs is generally very 
low, owing to the acidic conditions of the stomach and 
poor permeability across intestinal mucosa [11]. 
Enteric coated preparations are available, but they 
release the drug with a burst, leading to other 
gastrointestinal tract–related disorders thus aggravating 
the inflammatory conditions. In the present study, 
efforts have been made to prepare a biocompatible 
sustained release system for proteins and peptides with 
high biocompatibility and physico-chemical stability. 
Furthermore, lipid matrix materials might provide a 
less detrimental environment for peptides and proteins 
during the application.  
Use of the response surface methodology has been 
proven to be useful tool in the development and 
optimization of controlled release preparations [12].  
The objective of the investigation was to develop a 
sustained-release lipospheres of STP using wax and 
polar lipid combination which due to the gastro 
resistant lipid matrix used and prolonged release 
properties, may hinder drug discharge in the stomach, 
minimize unwanted effects of the drug on G.I.T and 
liver.   
A 32 factorial design is an established method to study 
the effect of selected parameters. The drug amount (X1) 
and Tween® 80 concentration (X2) were selected as 
independent variables while the mean diameter and the 
percent peptide content of lipospheres were chosen as 
the dependent variables in the present investigation. 
The levels for these 2 parameters were determined 
from the preliminary trials. Furthermore, formulations 
were evaluated for in-vitro release and proteolytic 
activity.  
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Materials and Methods 
 
Materials  
Serratiopeptidase (MW 52kDa) was received as gift 
sample from Advanced Enzyme Technologies Ltd, 
Nasik, India. Paraffin wax was purchased from 
Himedia labs. Cetyl alcohol, Tween® 80, potassium 
dihydrogen orthophosphate, disodium hydrogen 
orthophosphate and sodium hydroxide were purchased 
from S.D. Fine Chemicals Ltd. (India). All other 
chemicals used were of analytical grade. 
 
Preparation of Lipospheres  
Lipospheres were prepared by a method based on the 
water-in-oil-in-water double emulsion (w/o/w) method 
reported by Reithmeier et al (2001) and Cortesi et al 
(2002) with few modifications [4,13]. STP was 
solubilized in the 100µl internal aqueous phase of a 
w/o/w double emulsion containing Tween®20 (3% 
w/v) as stabilizer to prevent loss of STP to the external 
phase during solvent evaporation [14]. This aqueous 
solution of peptide was emulsified in 300mg of 
Paraffin wax and cetyl alcohol dissolved in 1.0ml of 
methylene chloride under vigorous vortex-mixing for 
10 seconds.  The obtained primary emulsion was 
further emulsified into a small volume (3.0ml) of a 
stabilizer (0.2%v/v Tween®80, 37°C) containing 
aqueous phase. Hardening of the oily internal phase 
resulting in encapsulation of the peptide was 
accomplished by pouring emulsion into 100ml of ice 
cold water maintained at 4 °C and stirred at 300 rpm. 
After 3–5 hours, microparticles were isolated by 
filtration, washed with ice cold water and dried at room 
temperature (25°C) for 24 hours. Preliminary studies 
were carried out to identify the process/formulation 
variables in order to select key variables (Table 1). 
Different values of ratios of paraffin wax: cetyl 
alcohol, Tween® 80 concentration, peptide amount and 
stirring speed at elevated temperature prior to cooling 
were studied in the preliminary studies to select the 
best formulations (to obtain discrete and free flowing 
LS with high yields and drug content) for further 
studies. Key variables were further optimized as per 32 
full factorial design and a total of 9 batches (SLS1 to 
SLS9) of STP lipospheres were produced (Table 2). 
The other formulation and processing variables were 
maintained constant during the process.  
 
 
 
Characterization 
Particle size 
Particle size analysis of STP-loaded lipospheres was 
performed by optical microscopy using a compound 
microscope (Erma, Tokyo, Japan) [9]. A small amount 
of dry lipospheres was suspended in purified water 
(10mL). The suspension was ultrasonicated for 5 
seconds. A small drop of suspension thus obtained was 
placed on a clean glass slide. The slide containing 
lipospheres was mounted on the stage of the 
microscope and 300 particles were measured using a 
calibrated ocular micrometer. The process was repeated 
for each batch prepared.  
Morphology 
The surface morphology and shape of the lipospheres 
were analyzed by scanning electron microscopy for 
selected batches (Leo, VP-435, Cambridge, UK). 
Photomicrographs were observed at ×303 
magnification operated with an acceleration voltage of 
15kV and working distance of 10mm was maintained. 
Microspheres were mounted on the standard specimen-
mounting stubs and were coated with a thin layer 
(20nm) of gold by a sputter-coater unit (VG Microtech, 
Uckfield, UK).  
Drug content  
Twenty milligrams of the dried lipospheres were 
accurately weighed. They were added to 5ml of ethyl 
acetate. After the lipospheres dissolved completely, 
5ml of phosphate buffer (pH-7.4) was added to this 
solution and mixed thoroughly. The resulting solution 
was filtered using a Whattman filter (0.45μm pore size) 
and analyzed for STP content by measuring absorbance 
in UV-spectrophotometer (Shimadzu UV-1700, 
Pharmaspec, Tokyo, Japan) at 229.5nm by the first-
derivative spectrophotometric method using phosphate 
buffer (pH-7.4) and ethanol mixture (1:1) as blank [15]. 
Results were expressed as mean (±SD) of 3 
experiments. The measured responses are shown in 
Table 3.  
In vitro release 
In vitro release of STP from lipospheres was evaluated 
in both acidic buffer (pH-1.2) and phosphate buffer 
(pH-7.4). Amount of lipospheres equivalent to 20mg of 
STP were transferred to the prewarmed dissolution 
media (20ml) and maintained at 37±0.5°C under 
stirring at 50rpm. Samples were withdrawn every hour 
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up to 12hrs and the volume was replaced immediately 
by fresh phosphate buffer. The sample withdrawn was 
centrifuged (3000rpm, 15min). The supernatant 
solution was filtered and analyzed for STP content by 
measuring absorbance in UV-spectrophotometer 
(Shimadzu UV-1700, Pharmaspec, Tokyo, Japan) at 
229.5nm by first derivative spectrophotometric method 
using phosphate buffer (pH-7.4) as blank. Results were 
expressed as mean (±SD) of 3 experiments. 
 
In vitro proteolytic activity 
Prepared lipospheres and plain STP solution were 
placed separately in 5ml of HCl buffer (pH-1.2) or 
phosphate buffer (pH-7.4) maintained at 37±0.5ºC and 
stirred constantly at 100rpm. After 2hrs, samples were 
recovered by centrifugation at 3000rpm for 15min at 
room temperature (n=3). 
The proteolytic activity was determined as per the 
method reported in Food Chemical Codex (2003). The 
assay was based on a 30min proteolytic hydrolysis of 
casein at 37 ºC and pH 7.0. Unhydrolyzed casein was 
removed by filtration and the solubilized casein was 
determined spectrophotometrically at wavelength of 
275nm. In this method, the protease activity is 
expressed as PU units of preparation derived from 
Bacillus subtilis var. and Bacillus licheniformis var. 
One bacterial protease unit (PU) is defined as quantity 
of enzyme that produces 1.5μg/ml equivalent of L-
tyrosine per minute under the condition of the assay. 
Activity of enzyme was calculated by equation: 
Where Au is the value obtained by subtracting blank 
reading from test reading, As absorption of standard 
solution, 1.89 the final volume in ml of reaction 
mixture, 30 the time of the reaction in minutes and w 
the weight of the original sample in ‘g’. 
 
Response Surface Analysis 
The results are expressed as second order polynomial 
equation of the following form (Eq 1): where, bi is the 
estimated coefficient for the factor Xi, while Yi is the 
measured response. The coefficients corresponding 
linear effects (b1 and b2), interaction (b12) and the 
quadratic effects (b11 and b12) were determined from 
the results of the experiment (STAT-EASE, design 
expert, 7.0.3). To assess the reliability of the model, a 
comparison between the experimental and predicted 
values of the responses is also presented in terms of 
%Bias in Table 3.  
)3(100% ×Ρ
−Ρ=
vaueredicted
valuealExperimentvalueredictedBias
Bias was calculated by equation 2: 
 
 
Results and Discussion 
Peptide loaded lipospheres  (SLS) were prepared by 
w/o/w double emulsion method using wax (Paraffin 
wax) and polar lipid (cetyl alcohol) with Tween® 80 
for improved entrapment of hydrophilic drugs [16]. 
Lipid based carriers were selected to eliminate the toxic 
effects associated with the use of polymers as carriers. 
Melt dispersion technique is commonly used for 
preparation of lipospheres but w/o/w double emulsion 
method was considered with the aim to possibly reduce 
the exposure to high temperature of thermolabile 
compounds, such as proteins and peptides.  
When the lipid solution in methylene chloride was 
used, the aqueous phase coalesced rapidly, especially 
when the emulsion was prepared by vortex-mixing. 
May be the use of additional stabilizers could improve 
the emulsion stability and the encapsulation efficiency 
in case of the w/o/w-solvent evaporation method. 
Tween® 20 and Tween® 80 were used as stabilizers in 
inner and outer aqueous phase respectively for 
liposphere formation and emulsion stabilization. 
Serratiopeptidase is a neutral protease with isoelectric 
point of 6.1 [17]. Drug loading has been reported to 
improve by adjusting the pH of the aqueous phase by 
suppression of ionization [18]. The solubility of STP 
and hence leaching into the outer aqueous phase 
increases as the pH of the solution increases above its 
isoelectric point. The pH of Tween® 80 aqueous 
solution is in the range of 6.0 to 6.5 and hence did not 
warrant pH adjustment [17].  
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The Paraffin wax due to its physical properties and 
behaviour in the intestinal lumen was used to prepare 
gastro-resistant SLS formulations using the adopted 
technique [19]. Since lipospheres produced with 
paraffin wax alone resulted in poor drug entrapment 
and release, efforts were made to enhance drug release 
from the lipospheres by incorporating a polar wax 
modifier like cetyl alcohol. Literature citations reveal 
that cetyl alcohol has been successfully employed as a 
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wax modifier to modulate drug release from wax 
microspheres [20]. Tween® 80 was used to stabilize 
the oil in water emulsion by reducing the interfacial 
tension between the hydrophobic wax dispersion and 
the external aqueous phase, producing an emulsified 
oily dispersion, which resulted in drug loaded 
lipospheres on cooling. Fatty alcohols like cetyl alcohol 
and stearyl alcohol have been reported to improve 
release and entrapment of hydrophilic peptide due to 
their polar hydrophilic nature [21].  
Different formulation variables have been found to 
affect the peptide loading, entrapment as well as 
release profile of lipospheres (Table 1). The 
preliminary LS formulations consisting of blends of 
paraffin wax and cetyl alcohol at 1:1 ratio, where a 1:2 
(peptide: lipid) ratio was used, are given in Table 1. 
The production yield of SLS prepared from all 
formulations were high (>85%). Cetyl alcohol itself 
exhibits emulsifying capability further stabilizing the 
primary emulsion [22]. Moreover it also imparts 
sphericity with smooth surface and modifies the release 
of the entrapped drug. As being polar lipid, it improves 
the entrapment of hydrophilic drugs [20]. The slight 
loss of solids could be attributed to the losses occurring 
during various steps of processing such as sticking of 
the lipid solution, adsorption on the glass wall during 
solidification or loss of lipospheres during the washing 
step etc.  
Table 1. Preliminary STP loaded LS formulations 
 
S.No Variables Code Values MD (µm) 
% Drug 
content 
% EE 
1. Stirring speed 
(rpm) 
LA 
LB 
LC 
500 
1000 
1500 
69.34±1.43 
30.05±1.52 
64.54±1.66 
7.50±0.34 
11.69±0.90 
3.63±0.42 
78.92±2.32 
69.05±2.76 
35.80±1.90 
2. Wax:Wax 
modifier 
(Paraffin 
wax:Ct.A)(w/w) 
LD 
LE 
LF 
1:2 
1:1 
2:1 
Aggregates 
19.67±1.03 
32.15±0.78 
3.89±0.47 
11.53±1.22 
6.79±0.98 
42.08±1.90 
66.06±1.73 
78.50±1.89 
3. Peptide amount 
(mg) 
LG 
LH 
LI 
50 
100 
150 
28.54±1.23 
32.98±1.22 
38.14±1.90 
8.56±1.22 
10.34±0.96 
6.56±0.91 
74.34±2.09 
70.98±2.42 
34.67±1.76 
*MD-Mean Diameter; EE-Entrapment efficiency; EAP-External aqueous phase; 
Cet.A-Cetyl alcohol 
 
Increase in stirring speed during second emulsification 
significantly affected the size. By adjusting the stirring 
speed during the emulsification process, it was possible 
to modify the size of the particles. Increasing the 
stirring speed from 500 to 1000 rpm, the mean 
diameter of particles progressively decreased (Table 1). 
But on further increase in stirring speed from 1000rpm, 
larger aggregates were formed due to increase in the 
surface free energy of smaller particles. Loading also 
increased with increase in stirring might be due to 
better dispersion of lipid particles [12]. Particles 
obtained at 1000rpm presented a spherical geometry 
with absence of interaction phenomenon. So, 1000rpm 
speed was selected for further studies. 
Incorporation of cetyl alcohol significantly affected the 
% drug loading of the formed SLS.  At 1:1 ratio of 
paraffin wax: cetyl alcohol maximum loading was 
obtained due to polar hydrophilic nature of cetyl 
alcohol [12]. Cetyl alcohol effected encapsulation 
because it might decrease the hydrophobicity of the 
wall matrix and served as a good wetting agent for the 
drug allowing it to be finely dispersed. With increase in 
paraffin wax content decreased loading was observed 
due to hydrophobicity of the wax matrix decreasing the 
amount of hydrophilic drug.  
By inspection of Table 1, it is obvious that by 
increasing the amount of peptide used in the 
preparation of lipospheres from 50mg to 150mg, size 
and loading of LS increased and the entrapment 
efficiency decreased significantly (P<0.05). This may 
be explained by the fact that as the ratio of drug to the 
lipid matrix increases, a reduced space becomes 
available for the drug to be entrapped. Inefficient 
encapsulation of drug due to inadequate dispersion 
makes it possible for the drug to remain on the outer 
surface of the particles. During the washing stage of the 
encapsulation process the drug on the outside appeared 
to have been removed, resulting in low drug yield. 
Similar results were obtained with verapamil solid lipid 
nanoparticles [23]. But after increasing the peptide 
amount to 150mg there was significant decrease in 
loading might be due to insufficient amount of lipid to 
surround the peptide. 
In order to gain further insight into the effects of 
peptide amount (factor X1) and other important process 
variables such as stabilizer (Tween® 80) concentration 
in outer aqueous phase (factor X2) on the properties of 
LS formulations, a 32 factorial design model was used 
to optimize the formulations (Table 2). Formulation LE 
prepared with paraffin wax: cetyl alcohol (1:1) with 
stirring speed of 1000rpm can offer a starting basis for 
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this purpose since it represented a more meaningful 
STP content in the formulation with uniform spherical 
discrete lipospheres.  
 
Table 2.  Full factorial experimental design layout with coded levels 
and actual values of variables 
 
*Values in parenthesis indicates coded values 
All the formulations prepared within the experimental 
design yielded smooth spherical lipospheres as evident 
from optical and SEM photographs (Fig 1, 2; SLS 6; 
Table 3). The mean diameter of prepared lipospheres 
ranged from 19.69-26.07µm.  
These were visible as dense spherical structure due to 
solid lipid matrix. In case of SEM photographs  
 
 
 
 
 
 
aggregates were visible might be due to some wax 
matrix clumping after drying. 
 
The mean diameter (Y1) and drug content (Y2) of 
lipospheres from the nine experiments were used to 
generate predictor equations for lipospheres with 
independent variables as peptide amount (X1) and 
Tween® 80 concentration (X2). Limit for these 
variables were selected from preliminary trials. The 
results of multiple regression analysis and analysis of 
variance (ANOVA) are summarized in Table 4.  
For estimation of coefficients in the approximating 
polynomial function (equation 2) applying uncoded 
values of factor levels, the least square regression 
method was used. A suitable polynomial equation 
involving the individual main effects and interaction 
factors was selected based on the estimation of several 
statistical parameters such as the multiple correlation 
coefficient (R2), adjusted multiple correlation 
coefficient (adjusted R2) and the predicted residual sum 
of squares (PRESS) were calculated by the design 
expert software 7.0.3.   
As presented in Table 4, the quadratic model was 
selected as a suitable statistical model for optimized 
formulation with maximum loading because it had the 
smallest value of PRESS (4.38 for Y2). PRESS is a 
measure of the fit of the model to the points in the 
design. The smaller the PRESS statistic is, the better 
the model fits to the data points [24].  
 
 
 
 
 
 
F. code 
Variable X1 
Peptide amount 
(mg) 
Variable X2 
Tween® 80 (%v/v) 
SLS1 30 (-1)* 0.1(-1) 
SLS2 60(0) 0.1(-1) 
SLS3 90(+1) 0.1(-1) 
SLS4 30(-1) 0.15(0) 
SLS5 60(0) 0.15(0) 
SLS6 90(+1) 0.15(0) 
SLS7 30(-1) 0.2(+1) 
SLS8 60(0) 0.2(+1) 
SLS9 90(+1) 0.2(+1) 
MD (µm) (Y1) Drug content (%)Y2 
F. code % Yield 
Exp Pred % Bias Exp Pred % Bias 
% EE 
SLS1 85.20±2.54 25.78 25.71 -0.27 3.64 3.48 -4.59 78.90±1.43 
SLS2 83.36±3.41 25.98 25.38 -2.36 4.52 4.52 0 70.45±1.76 
SLS3 84.58±1.89 26.07 26.74 2.50 5.80 5.96 2.68 69.06±1.55 
SLS4 84.24±2.8 22.46 23.11 2.81 9.65 9.89 2.42 80.56±2.32 
SLS5 86.77±2.05 22.90 23.08 0.77 10.35 10.51 1.52 79.46±1.79 
SLS6 87.51±3.05 25.56 24.73 -3.35 11.93 11.53 -3.46 70.08±2.04 
SLS7 88.23±2.48 20.43 19.85 -2.92 8.51 8.43 -0.94 70.77±2.33 
SLS8 87.48±2.90 19.69 20.11 2.08 8.78 8.62 -1.85 69.54±1.62 
SLS9 89.24±2.67 21.90 22.06 0.72 8.99 9.23 2.60 68.90±1.80 
Table 3. Experimental and predicted responses obtained for the studied parameters  
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Table 4. Summary of results of a) model analysis b) lack of fit c)  
R-square analysis for measured responses 
  
(Mean Diameter) Y1 (%Drug content) Y2 
Source 
Sum of 
squares P>F Sum of squares 
P>F 
Model analysis  
Mean vs total  
Linear vs. mean 
2FI vs. linear 
Quadratic vs. 2FI 
Cubic vs. quadratic 
Residual 
Total  
 
4936.00 
45.60 
0.35 
1.64 
2.42 
0.071 
4986.08 
 
 
0.0007 
0.5452 
0.4682 
0.1689 
 
578.72 
29.33 
0.71 
31.08 
0.32 
0.056 
640.22 
 
 
0.1431 
0.7513 
0.0013 
0.3835 
R-square analysis Adjusted R-
square 
PRESS Adjusted R-square PRESS 
Linear 
2FI 
Quadratic 
Cubic 
0.8806 
0.8678 
0.8672 
0.9886 
10.04 
15.42 
30.07 
12.96 
0.3026 
0.1815 
0.9835 
0.9927 
67.92 
115.70 
4.38 
10.21 
 
 
From the p-values presented in table 4, it can be 
concluded that for both responses the cross product 
contribution (2FI) of the model was not significant 
indicating the absence of interaction effects. The results 
of multiple regression analysis and analysis of variance 
test (ANOVA) are summarized in Table 5. 
 
Table 5. Regression analysis data for measured responses 
 
MD (µm)Y1 Drug content (%) Y2 
Coefficients 
FM RM FM RM 
b0 23.08 23.42 10.51 8.02 
b1 0.81 0.81 0.82 0.82 
b2 -2.63 -2.63 2.05 2.05 
b11 0.84 - 0.20 - 
b22 -0.33 - -3.94 - 
b12 0.29 - -0.42 - 
R2 0.9502 0.9104 0.9938 0.4770 
Significance 0.0361 0.0007 0.0016 0.1431 
F 11.45 30.50 96.28 2.74 
 
*FM-Full Model; RM-Reduced Model 
The mean diameter and percent drug content of STP 
lipospheres showed R2 values of 0.9502 and 0.9938 
(Table 5), respectively; indicating good fit, and it was 
concluded that the second-order model adequately 
approximated the true surface. Furthermore, low value 
of %bias for all batches showed good agreement 
between predicted and experimental values as shown in 
Table 3.  
The predictor equation generated for the mean diameter 
(MD) was found to be significant with an F-value of 
30.50 (p < 0.0007) and R2 value of 0.9104 (equation 4): 
)4(63.281.008.23)( 211 −−+= XXMDY
 
The equation generated revealed that both main factors 
independently exerted a significant influence on the 
mean diameter. The influence of the main effects on 
the particle size of the lipospheres was further 
elucidated using the response surface plot (Figure not 
shown).                
The predictor equation generated for the drug content 
was found to be significant with an F-value of 86.00 
(p< 0.0001) and R2 value of 0.9810 (equation 5): 
)5(94.305.282.051.10)(% 22212 −−++= XXXcontentDrugY
                                                                     
The equation generated revealed the absence of 
interaction effect with contribution of each effect 
especially of Tween® 80 concentration (Factor X2).  
 
Table 6. Release behavior of STP in phosphate buffer (pH 7.4) from SLS1-
SLS9 
 
First order Higuchi Ritger-Peppas Formulation 
code k R2 K R2 n R2 
SLS1 0.099 0.996 21.85 0.994 0.516 0.994 
SLS2 0.108 0.993 22.52 0.995 0.513 0.996 
SLS3 0.135 0.968 24.42 0.993 0.515 0.996 
SLS4 0.131 0.978 24.67 0.995 0.536 0.997 
SLS5 0.128 0.976 24.00 0.994 0.515 0.996 
SLS6 0.142 0.968 24.57 0.992 0.504 0.992 
SLS7 0.154 0.948 25.83 0.991 0.542 0.994 
SLS8 0.158 0.960 25.11 0.996 0.490 0.997 
SLS9 0.216 0.927 26.09 0.988 0.468 0.987 
 
*K, Release rate constant; R2, coefficient of determination; n, release exponent 
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For the mean diameter (Y1) and percent drug content 
(Y2) of STP lipospheres (SLS), the calculated F values 
11.45 and 96.28 respectively, were found to be greater 
than the critical (statistical table value) value of F 5, 3, 
95% (9.01) and hence it may be concluded that one 
variable contributes significantly in the regression. The 
break up of source sum of squares (Source SS) in 
ANOVA indicated that the contribution of factor X2 
(Tween® concentration) (SSY1 = 41.66; SSY2 = 25.30) 
is much higher than factor X1 (Drug concentration) 
(SSY1 = 3.94; SSY2 = 4.03) for optimizing the mean 
diameter as well as drug content of lipospheres. The 
interaction terms X1X2 and the polynomial terms X1X1 
and X2X2 indicated insignificant values of individual 
source sum of squares. Interaction effect was further 
investigated by testing the model in portions [25].  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
The calculated value of F for effect on mean diameter 
and % drug content were found to be 0.799 and 81.48 
respectively. The critical (statistical table value) value 
of F 3, 3, 95% is 9.28. In case of mean diameter, the 
calculated value of F is lower than the critical table 
value, we conclude that the interaction do not 
significantly contribute for the prediction of mean 
diameter in the microspheres. But, in case of drug 
content interaction between variables (X1 and X2) is 
significant indicating the combined role of X1 and X2 
on determining the response Y2, effect of X2 being 
significant comparatively.  
2  
1  1 
Fig 1. Photomicrographs & Fig 2. SEM photographs of SLS6 lipospheres 
Response surface plots indicate the negative effect of 
Tween® 80 on MD (Y1) of lipospheres. This result was 
entirely relevant to the higher dispersion property of 
the higher emulsifier concentration in formulation LS6 
(X2, 0), resulting in decreasing the interfacial tension 
and formation of smaller particles. Similar results were 
reported by Gibaly and Ghaffar (2005), while 
encapsulating allopurinol in beeswax-ceryl alcohol 
lipospheres prepared by melt dispersion technique [26].  
STP at high level (X1, +1) and Tween® 80 at medium 
level (X2, 0) yielded microspheres with highest drug 
content (11.93±0.89%) which may be due to increased 
availability of drug at higher at high STP level and 
better dispersion obtained at medium level of Tween® 
80 stabilizer. When X1 was set at high level (+1) and  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 Fig 3. 3D surface curve for the effect of selected variables on the drug content of lipospheres 
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X2 was set either at low (-1) or at high level (+1) less 
than 11.93% of the drug was loaded in the lipospheres.  
At both low and high level of (Tween® 80) X2, lower 
drug content was found and maximum loading was 
found at medium level. Possible reason for decreased 
loading at low level of X2 is decreased viscosity and at 
higher concentration of Tween® 80 in external aqueous 
phase leads to high water content and high wettability 
resulting into decreased loading [27]. Moreover, as for 
Tween® 80, its CMC is ~0.014mol/L whereby at a 
higher concentration of Tween® 80 than its Critical 
Micelle Concentration (CMC) sphere-shaped micelles 
are formed which further transform into cylinder-
shaped micelle structures [28].  
Figure 3 represent the response surface plot, which 
shows the effects of the X1 and X2 on the drug content 
of lipospheres. As can be seen through the response 
surface graphs, X1 is the most significant factor 
effecting drug content whereas X2 affects size as well 
as drug content of lipospheres significantly. 
The positive coefficient of X1 and negative coefficient 
of X2 in case of Y1 response (equation 4) refers to the 
positive influence of drug amount and negative 
influence of Tween® 80 on the size of lipospheres. 
Similarly, equation (equation 5) for drug content of 
lipospheres depicts the positive coefficient of X1 and 
X2 on the drug content of lipospheres (Fig 3).  
Increase in peptide amount increased the drug loading 
with subsequent decrease in entrapment efficiency 
(Table 3). This may be explained by the fact that as the 
ratio of peptide to the lipid matrix increases, a reduced 
space becomes available for the peptide to be entrapped 
[29]. Inefficient encapsulation of peptide makes it 
possible to remain on the outer surface of the particles. 
During the washing stage of the encapsulation process 
the peptide on the outside appeared to have been 
removed, resulting in low entrapment. 
Contour plots show that various combinations of X1 
and X2 may satisfy any specific requirement (in this 
case- size in range and maximum peptide content) 
while taking into consideration other factors such as 
cost, stability etc. The results from the estimated ridge 
of maximum response in terms of desirability revealed 
that optimum peptide amount (X1) and Tween® 80 
(X2) were 90mg and 0.16%v/v for desirable response. 
Release of STP from SLS1-9 in phosphate buffer (pH-
7.4) was faster than that into acidic buffer (pH-1.2) 
reflecting differences in extent to which the peptide  
 
 
 
 
 
 
 
 
 
 
 
 
Fig 4. In vitro release profile of serratiopeptidase in phosphate 
buffer (pH-7.4) from lipospheres formulations (SLS1-9)
 
 
dissolved in the two fluids. A maximum drug release of  
16.87–28.3% was observed for all the formulations in 
acidic buffer (pH 1.2) after 4 h (figure not shown). On 
the other hand, more than 80% of STP was rapidly 
released from these formulations within 12 h in 
phosphate buffer (pH-7.4) and complete release 
occurred in about 24 h (Fig 4). Thus, the formulation 
could protect the peptide from gastric degradation and 
would release its drug load slowly at pH 7.4. Release 
pattern of all formulations was similar with difference 
in the burst release. Burst effect was more persistent in 
the formulations with higher STP content due to the 
surface located peptides. These findings are in 
agreement with those of Adeyeye and Price (1994) and 
Giannola and De Caro (1997) who reported that rapid 
drug release (such as phenytoin and diclofenac sodium) 
from fatty acid or alcohol-wax microspheres would be 
expected due to the hydrophilicity and leaching 
characteristics [30,31].  
The faster dissolution with increased drug load can be 
explained by peptide present outside the LS and 
presumable increase in channels and number of pores 
(produced by the drug release) within the wax matrix. 
This effect caused a decrease in diffusion path length 
through the released part region and enhanced drug 
release [29,30].  
Drug release kinetics from the STP formulations 
SLS1–SLS9 were examined at pH 7.4. The release 
curves for STP showed a non-linear drug dissolution 
pattern (Fig. 6) and the drug release from the LS was 
affected by the drug content and the LS size, in 
addition to the structure of the matrix. All formulations 
showed an initial burst from 20.89±1.87% to 
27.89±2.03% in one hour with additional 73.22±2.36% 
to 94.75±2.78% in next 12 hours. There was significant 
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effect of variable X1 (Peptide amount) as compared to 
X2 (Tween® 80) on the initial burst. Peptide amount 
exhibited relative positive effect on the initial burst due 
to increased loading and decrease in lipid to peptide 
ratio causing loss of drug (Formulations SLS3, 6 and 
9). The cumulative percentage release of STP after 12h 
was found to be higher for batches with high STP and 
Tween® 80 content.  
The release rates were analyzed by least square linear 
regression method. Release models such as first order 
model, Higuchi model and Ritger-Peppas empirical 
model were applied to the release data (Table 6) 
[32,33]. Using the Ritger–Peppas model, a plot of the 
logarithm of the fractional solute release versus the 
logarithm of time (between 1 and 12 h) yielded a 
straight line with a determination coefficient (R2) of 
0.992–0.997 for the nine formulations. The slope of 
this line determines the diffusional exponent (n) value, 
which is characteristic of the transport mechanism of 
diffusional release. This equation may be used only for 
a granular inert matrix system which maintains a 
constant planar surface area, where the drug diffusion 
coefficient is clearly concentration independent and the 
effect of solubility is implicit. But the value of n 
obtained was between 0.490-0.542 which indicates 
non-Fickian (anomalous) release referring to a 
combination of both diffusion and erosion controlled-
drug release (Siepmann and Peppas, 2001). Results 
supported the diffusional release kinetics and also the 
erosion or solubilization of the wall matrix-driven 
phenomena. The value of coefficient of determination 
(R2) in Higuchi equation was found to be >0.9 in 
alkaline buffer medium which again indicates the 
diffusion-controlled release. The result obtained is 
supported by the literatures reported on ibuprofen and 
diclofenac loaded wax microspheres [29, 30]. 
The quicker drug release at low wax loads can be due 
to increased peptide positioned on the liposphere 
surface that remained exposed to the dissolution fluid. 
At higher peptide loads, drug dissolution resulted in a 
subsequent increase in the number of channels and 
pores within the wax matrix, which decreased the 
diffusional path length through the drug depleted zone 
and enhanced drug release [30].  
The lipospheres showed about 6.35-7.08% loss of 
proteolytic activity in acidic medium whereas retention 
of activity in basic medium was found to be 97.90-
98.26%. Meager loss of activity in alkaline media may 
be due to processing steps involved in preparation of 
formulation. At the same time plain STP solution 
exhibited almost complete loss of activity in acidic 
medium and 86.84% activity was retained in alkaline 
medium. SLS exhibited much better retention of 
proteolytic activity as compared to plain STP solution. 
Possible explanation for the improved physical and 
chemical stability of proteolytic enzyme might be due 
to reduced mobility and retention of peptide in solid 
lipid matrix. 
 
Conclusion 
Lipospheres can be considered as a promising delivery 
system for oral delivery of peptide drugs like enzymes. 
Lipospheres were able to entrap the peptide at high 
levels and sustain its release over a prolonged time. 
STP wax LS developed by a factorial design had high 
drug content and showed sustained-release and enteric 
behavior suitable for oral use. Increase in peptide load 
increased the rate of drug release whereas Tween® 80 
concentration decreased the size of lipospheres with 
improvement in peptide content. The encouraging 
results obtained in this study could propose lipospheres 
for future in vivo studies. These novel lipospheres were 
found to be promising for protection of the protein and 
peptides exhibiting better therapeutic effect. But, 
further studies in terms of pharmacokinetics, 
toxicology and animal studies are required for clinical 
utility of the formulation. 
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